PSA isoforms in prostate cancer detection

European Urology, Supplements

Volumn 5, Issue 6, 2006, Pages 495-499

  Özen, Haluk ^a,c   Sözen, Sinan ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Diagnosis; Prostate cancer; Prostate specific antigen; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOSYNTHESIS; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; CONFERENCE PAPER; HUMAN; PRECURSOR; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

EID: 33644852174     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.017     Document Type: Conference Paper

References (24)

1. American Cancer Society. Cancer Facts and Figures. Available at: www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf, 2005.
2. T.A. Stamey, M. Caldwell, and J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172 2004 1297 1301
3. W.J. Catalona, and A. Loeb The PSA era is not over for prostate cancer Eur Urol 48 2005 541 545
4. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1975-2002. Bethesda (MD): National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2002. November 2004 SEER data submission, posted to the SEER website 2005.
5. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre N Engl J Med 350 2004 2239 2246
6. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate specific antigen J Clin Oncol 21 2003 383 391
7. W.J. Catalona, A.W. Partin, and K.M. Slawin Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542 1547
8. H. Ozen, C. Aygun, A. Ergen, S. Sozen, F.T. Aki, and M.C. Uygur Combined use of prostate specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer Am J Clin Oncol 24 2001 610 613
9. M.K. Brawer, C.D. Cheli, and I.E. Neaman Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer J Urol 163 2000 1476 1480
10. T. Okegawa, H. Noda, K. Nutahara, and E. Higashihara Comparisons of the various combinations of free, complexed, and total prostate specific antigen for the detection of prostate cancer Eur Urol 38 2000 380 387
11. K. Jung, U. Elgeti, M. Lein, and B. Brux Ratio of free or complexed prostate specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 46 2000 47 54
12. X. Filella, J. Alcover, R. Molina, J.M. Corral, P. Carreto, and A. Ballesta Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostatic hyperplasia Prostate 42 2000 181 185
13. T.A. Stamey, and C.E. Yemoto Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume J Urol 163 2000 119 126
14. M.C. Miller, G.J. O'Dowd, A.W. Partin, and R.W. Veltri Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics Urology 57 2001 1105 1111
15. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen, and I. Ross A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer J Urol 165 2001 1549 1553
16. S. Tanguay, L.R. Begin, M.M. Elhilali, H. Behlouli, P.I. Karakiewicz, and A.G. Aprikian Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection Urology 59 2002 261 265
17. S. Sözen, S. Eskicorapci, B. Kupeli, and L. Irkilata Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study Eur Urol 47 2005 302 307
18. A.W. Partin, M.K. Brawer, and G. Bartsch Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial J Urology 170 2003 1787 1791
19. A.W. Roddam, M.J. Duffy, and F.C. Hamdy Use of prostate specific isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis Eur Urol 48 2005 386 389
20. S.D. Mikolajczyk, and H.G. Rittenhouse Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer Keio J Med. 52 2003 86 91
21. L.J. Sokoll, D.W. Chan, and S.D. Mikolajczyk Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis Urology 61 2003 274 276
22. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 2003 2181 2185
23. M. Lein, A. Semjonow, and M. Graefen A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen J Urol 174 2005 2150 2153
24. E.I. Canto, H. Singh, and S.F. Shariat Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer Urology 63 2004 905 911